



ELSEVIER

Contents lists available at ScienceDirect

## Z. Evid. Fortbild. Qual. Gesundh. wesen (ZEFQ)

journal homepage: <http://www.elsevier.com/locate/zefq>

Evidenz in der Gesundheitsversorgung / Evidence in Health Care

## Research on point-of-care tests in outpatient care in Germany: A scoping review and definition of relevant endpoints in evaluation studies

*Forschung zu Point-of-Care-Tests in der ambulanten Versorgung in Deutschland: Scoping-Review und Definition relevanter Endpunkte für Evaluationsstudien*Anni Matthes <sup>a,b</sup>, Jutta Bleidorn <sup>a</sup>, Robby Markwart <sup>a,b,\*</sup><sup>a</sup> Jena University Hospital, Institute of General Practice and Family Medicine, Friedrich Schiller University Jena, Germany<sup>b</sup> InfectoGnostics Research Campus Jena, Jena, Germany

## ARTICLE INFO

## Article History:

Received: 19 January 2022

Received in revised form: 14 March 2022

Accepted: 13 June 2022

Available online: xxxx

## Keywords:

Point-of-care tests

POCT

Rapid tests

Scoping review

Outpatient care

Germany

## ABSTRACT

**Background:** The fast turnaround time and user-friendliness of point-of-care tests (POCTs) offer a great potential to improve outpatient health care where clinical decisions have to be made during the physician-patient encounter and time resources are limited. The aim of this scoping review is to describe the extent and nature as well as gaps in German research activities on POCT in outpatient care. In addition, we define research endpoints that should be addressed in the comprehensive evaluation of POCTs targeted for outpatient care.

**Methods:** We performed a scoping review with a systematic literature search in Medline (via PubMed), Scopus, Web of Science, Cochrane library and Google Scholar for German publications on POCT with relevance to German outpatient care published from January 2005 to November 2020.

**Results:** Our literature search identified 2,200 unique records. After literature selection 117 articles were included in this scoping review. Just over half of the articles (67/117, 57.3%) were primary research studies with original data, while one third of all the studies (33.3%) were secondary research articles (e.g., review articles). The remaining articles were clinical recommendations / position papers (7/117, 6.0%) and other types of articles (3.4%). The majority of articles focused on POCT use in infectious diseases (44/117, 37.6%), diabetic syndromes (15.4%), cardiac disease (12.0%) or coagulopathies and thrombosis (10.3%), while the remaining articles did not specify the disease (13.7%) or investigated other diseases (11.1%). Similar to international studies, most primary research studies investigated the diagnostic performance of POCT (e.g., sensitivity, specificity). Evidence beyond diagnostic accuracy remains scarce, such as the impact on therapeutic decisions and practice routines, clinical effectiveness, and user perspectives. In line with this, interventional studies (such as RCTs) on the effectiveness of POCT use in German outpatient care are limited. We define six endpoint domains that should be addressed in the evaluation of POCTs targeted for outpatient care: (i) diagnostic performance, (ii) clinical performance, (iii) time and costs, (iv) impact on clinical routines / processes, (v) perspectives of medical professionals and patients, and (vi) broader aspects.

**Conclusion:** There is considerable research activity on POCTs targeted for use in outpatient care in Germany. Data on their potential benefits beyond diagnostic accuracy is often lacking and should be addressed in future POCT research studies.

## ARTICLE INFO

## Artikel-Historie:

Eingegangen: 19. Januar 2022

Revision eingegangen: 14. März 2022

Akzeptiert: 13. Juni 2022

Online gestellt: xxxx

## ZUSAMMENFASSUNG

**Hintergrund:** Aufgrund ihrer Schnelligkeit und Anwenderfreundlichkeit besitzen Point-of-Care-Tests (POCT) großes Potenzial, die Patientenversorgung im ambulanten Versorgungsbereich zu verbessern, da dort klinische Entscheidungen direkt während des Arzt-Patient-Kontakts getroffen werden müssen und Zeitressourcen knapp sind. Ziel dieses Scoping-Reviews ist es, den Umfang, die Art sowie potenzielle

Abbreviations: CRP, C-reactive protein; POCT, point-of-care tests; RCT, randomized controlled clinical trials

\* Corresponding author. Robby Markwart, Jena University Hospital, Institute of General Practice and Family Medicine, Bachstraße 18, 07743 Jena, Germany.

E-mail address: [robby.markwart@med.uni-jena.de](mailto:robby.markwart@med.uni-jena.de) (R. Markwart).<https://doi.org/10.1016/j.zefq.2022.06.002>

1865-9217/© 2022 Published by Elsevier GmbH.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

**Schlüsselwörter:**  
 Point-of-care-Tests  
 POCT  
 Schnelltests  
 Scoping-Review  
 Ambulante Versorgung  
 Deutschland

Lücken der deutschen Forschungsaktivitäten hinsichtlich POCT für die ambulante Versorgung zu beschreiben. Darüber hinaus werden Endpunkte definiert, die bei der Evaluation von POCT adressiert werden sollten.

**Methoden:** Ein Scoping-Review mit systematischer Literaturrecherche in Medline (via PubMed), Scopus, Web of Science, Cochrane Library und Google Scholar nach deutschen wissenschaftlichen Publikationen zu POCT für die ambulante Versorgung wurde durchgeführt (Publikationsdatum: Jan. 2005 bis Nov. 2020).

**Ergebnisse:** In der Literaturrecherche wurden 2200 Artikel identifiziert, von denen nach der Literaturauswahl 117 Artikel in dieses Scoping-Review eingeschlossen wurden. Knapp über die Hälfte der Artikel (67/117; 57,3%) stellten Primärstudien mit Originaldaten dar, während ein Drittel (33,3%) Sekundärstudien (z. B. Literaturreviews) waren. Darüber hinaus wurden sieben (6,0%) klinische Empfehlungen / Positionsstatements und vier sonstige Artikeltypen identifiziert.

Die überwiegende Anzahl der Artikel untersuchte POCT bei Infektionskrankheiten (44/117; 37,6%), Diabeteserkrankungen (15,4%), Herzerkrankungen (12,0%) sowie Koagulopathien und Thrombosen (10,3%). 16 Artikel (13,7%) fokussierten auf keine spezielle Erkrankung, und 13 Artikel (11,1%) untersuchten POCTs bei sonstigen Erkrankungen.

Vergleichbar mit internationalen POCT-Studien untersuchten auch deutsche POCT-Primärstudien überwiegend die Testgüte von POCT (z. B. Sensitivität, Spezifität). Selten wurden Outcomes untersucht, die über die Testgüte hinausgehen, wie z. B. Einfluss von POCT auf therapeutische Entscheidungen, patientenrelevante Outcomes und Anwenderperspektiven. Wie in der internationalen POCT-Forschung werden auch in Deutschland nur vereinzelt Interventionsstudien (z. B. RCTs) zum Nutzen des POCT-Einsatzes in der ambulanten Versorgung durchgeführt.

Wir definieren sechs Endpunktdomänen, die bei der Evaluation von POCT in der ambulanten Versorgung adressiert werden sollten: (i) diagnostische Performance, (ii) klinische Performance, (iii) Zeit und Kosten, (iv) Einfluss auf klinische Routinen / Prozessabläufe, (v) Perspektiven und Einstellungen des medizinischen Personals und von Patient:innen sowie (vi) weitergehende Aspekte.

**Schlussfolgerungen:** In Deutschland gibt es umfangreiche Forschungsaktivitäten im Bereich POCT für den ambulanten Versorgungsbereich. Über die Testgüte hinausgehende Evidenz zum potenziellen Nutzen von POCT fehlt aber überwiegend und sollte in zukünftigen Studien stärker adressiert werden.

## Introduction

Point-of-care-tests (POCTs), also referred to as rapid tests, are in-vitro laboratory procedures that are performed in close proximity to patients and are characterized by their fast turnaround time as they typically yield results within 15 min [1,2]. Examples for POCTs typically used in outpatient care include tests for plasma glucose, Troponin and urine dip sticks (pH-value, leucocyte count, protein level, etc.). In contrast to standard laboratory tests carried out in external laboratories, POCT have the potential to directly impact therapeutic and/or diagnostic decision making at the index consultation. This is particularly important in the management of patients in outpatient care where rapid clinical decisions have to be made and time resources are limited. In the last decade, many novel POCT have been developed and the size of the POCT market has steadily increased and is expected to further increase in the future [3]. Although a relatively large number of POCT are now available for diagnostic use in Germany and other countries, many of them are not routinely used in outpatient care [4,5]. This can be explained by several factors, such as concerns about accuracy, over-reliance on tests and limited usefulness [6] as well as structural barriers including a lack of reimbursement.

POCT use in routine outpatient healthcare should be based on the principles of evidence-based medicine. Clinical studies that investigate the effects of POCT diagnostics are therefore necessary. However, while there are often sufficient data on the diagnostic accuracy of POCT (e.g. sensitivity, specificity), the impact of POCT on other relevant outcomes, such as patient health or broader impact, is rarely addressed in clinical studies [7]. Since the clinical performance of healthcare interventions might be significantly influenced by the study setting and location [8,9], study results may not be transferable to settings and regions in other countries. In order to evaluate the diagnostic and clinical value of POCT in outpatient care in Germany, it is therefore necessary that such studies are conducted in the German outpatient healthcare setting.

The aim of our scoping review [10] is to describe the extent and nature as well as gaps of POCT research in outpatient care in Germany. In particular, we describe the studied endpoints of research articles on POCT use and define endpoints that should be addressed in the comprehensive evaluation of POCT targeted for outpatient care.

## Methods

This scoping review was conducted according to recognised guidelines on the methodology of scoping reviews [10–12]. The methodology of a scoping review was chosen, because it allows to identify knowledge gaps, scope a body of literature, and to investigate research conduct [13].

### Search strategy and study selection criteria

We systematically searched Medline (via PubMed), Scopus, Web of Science, Cochrane library and Google Scholar for publications published from January 2005 to November 2<sup>nd</sup> 2020 (date of last search). The detailed search strategy, including search strings and applied filters, is provided in [Supplementary Material](#). An abstract and title screening of all search results was performed and potentially relevant articles were retrieved for full-text review. The study selection was independently performed by two investigators (AM, RM) using the Rayyan software [14]. Rayyan is a professional software application which helps expediting and organising the literature screening process and was developed by the Qatar Computing Research Institute and Cochrane Bahrain. Discordances were solved by discussion.

Studies were included if they met all of the following criteria:

- Publication type: Full research articles (primary or secondary literature), clinical recommendations and guidelines,

conference abstracts and academic theses (master's theses, PhD theses, habituations). Studies must be published after 2004.

- Focus on POCTs: The publication's focus is on POCT or the publication provides substantial information on POC diagnostics. In our study POCT encompass laboratory tests that can be performed in close proximity to patients (i.e. in the physicians' office) without extensive laboratory equipment or manual procedures. Although most POCTs yield results within 15min, we accepted a maximum of 60min turnaround time.
- Setting: The clinical setting encompasses outpatient care, including ambulatory emergency care. Studies with clear focus on POCT use in a hospital setting were excluded.
- Focus on Germany: Studies were included if they were conducted in Germany or involved authors with an affiliation of a German institution (academia or industry). Clinical recommendations and guidelines were included if they were specifically tailored for Germany.

#### Data extraction

Data of all eligible studies were independently extracted by two authors (AM, RM) using standardized forms. All disagreements were resolved through discussion. The following study characteristics and data were extracted: Title, first author, year of publication, study period, publication type, main topics in regard to POCT, setting in outpatient care (e.g. general medicine, emergency medicine, etc.), study population (e.g. patients, medical professional staff, POCT stakeholder, etc.), disease (e.g. respiratory disease, cardio-vascular disease, etc.), characteristics of POCT, overall conclusion of study authors in regard to POCT use (i.e. favourable or not favourable in the context of the study).

#### Results and data synthesis

In the systematic literature search we identified 2200 unique records. After title and abstract screening, 808 studies were assessed in full-text review. In total, we identified 117 articles [15–131] on POCT use in outpatient care in Germany published between 2004 and 2020 (Figure 1).


#### Publication characteristics

The majority (72.6%, 85/117) of articles were full research articles. Conference abstracts / posters and academic theses accounted for 10.3% and 11.1% of all articles, respectively. Seven clinical recommendations / position papers (6.0%) with primary focus on POCT application in outpatient care were found.

Just over half of the articles (67/117, 57.3%) were primary studies that collected original data on POCT use or development (Table 1). Among these 67 primary studies, the great majority (62/67, 92.5%) were non-interventional studies, while only five (7.5%) provided results from interventional clinical studies. Out of these, one was a randomized controlled trial (RCT) and four were either non-randomized controlled trials ( $n = 2$ ) or uncontrolled trials ( $n = 2$ ).

Out of all included studies, one-third (39/117, 33.3%) were secondary research articles, with most of them (87.2%) being narrative reviews / expert opinions and the remaining five articles being systematic reviews and scoping reviews. The majority of articles were published in English (74/117, 63.2%) but over one third (36.7%) of all identified articles were exclusively published in German with English abstract available in most cases. The remaining articles were clinical recommendations/ position papers (7/117, 6.0%) and articles of other types (4/117, 3.4%)

The majority of articles focused on POCT use in infectious diseases (44/117, 37.6%), diabetic syndromes (15.4%), cardiac diseases (12.0%) or coagulopathies and thrombosis (10.3%) (Table 2). Sixteen out of 117 studies (13.7%) did not specify the disease and 13 studies (11.1%) focused on other diseases, such as cancer or allergic diseases. Among the 44 studies on POCT use in infectious diseases, most studies (61.4%, 27/44) investigated POCT for the detection of pathogens, while seven (15.9%) focused on POCT measurements of inflammatory markers, such as C-reactive protein or procalcitonin. Articles on POCT use in diabetic syndromes ( $n = 18$ ) predominantly investigated POCT glucose measurement (77.8%, 14/18) while the remaining four studies (22.2%) evaluated POCT for glycosylated hemoglobin (HbA1c). Among the 14 studies on POCT use in cardiac diseases (e.g. cardiac infarction or insufficiency), eight studies (57.1%, 8/14) investigated natriuretic



**Figure 1.** Flow chart of study selection.

**Table 1**

Articles types of articles on POCT use in German outpatient care published between 2005 and 2020.

Article type	Total number	(%)	References
<b>Primary research studies</b>	<b>67</b>	<b>(57.3)</b>	
Randomized controlled intervention study (RCTs)	1	(1.5)	[1]
Non-randomized controlled intervention studies	2	(3.0)	[2,3]
Uncontrolled intervention studies (i.e. pre-post studies)	2	(3.0)	[4,5]
Non-interventional studies	62	(92.5)	[6–67]
<b>Secondary research articles (review articles / experts opinions)</b>	<b>39</b>	<b>(33.3)</b>	[68–106]
<b>Clinical guidelines / recommendations and positions papers</b>	<b>7</b>	<b>(6.0)</b>	[107–113]
<b>Others</b>	<b>4</b>	<b>(3.4)</b>	[114–117]
<b>Total</b>	<b>117</b>	<b>(100)</b>	

**Table 2**

Disease focus in articles on POCT use in German outpatient care published between 2005 and 2020.

	Total number	(%)	References
<b>Total number of studies</b>	<b>117</b>		
Infectious diseases	44	(36.7)	[1–44]
Diabetic syndromes	18	(15.4)	[45–62]
Cardiac syndromes (e.g. cardiac infarction or insufficiency, etc.)	14	(12.0)	[63–76]
Coagulopathies and thrombosis	12	(10.3)	[77–88]
Unspecified diseases	16	(13.7)	[89–104]
Others	13	(11.1)	[105–117]
<b>Total</b>	<b>117</b>	<b>(100)</b>	

**Table 3**

Research focus and studied outcomes in primary research studies on POCT use in German outpatient care published between 2005 and 2020\*.

	Total number	(%)	References
<b>Total number of primary studies</b>	<b>67*</b>	<b>(100)</b>	
<b>Preclinical research</b>			
Technical development/preclinical basic research	9	(13.4)	[1–9]
<b>Diagnostic performance</b>			
Technical and clinical diagnostic test performance	40	(59.7)	[10–49]
<b>Clinical performance</b>			
Impact on therapeutic decisions	4	(5.9)	[15,50–52]
Clinical effectiveness (patient health outcomes)	2	(3.0)	[13,50]
<b>Time and costs</b>			
Time-related aspects (e.g. time to result, time saving, etc.)	6	(9.0)	[31,45,50,53–55]
Costs (e.g. total costs, cost effectiveness, etc.)	2	(3.0)	[13,56]
<b>Impact on clinical routines / processes</b>			
Implementation (e.g. training, quality assurance, etc.)	11	(16.4)	[31,36,37,45,50,53–55,57–59]
<b>Perspectives of medical professionals and patients</b>			
Medical professionals	4	(6.0)	[3,53,55,58]
Patients*	2	(3.0)	[55,58]
<b>Broader aspects</b>			
Frequency of use in routine healthcare and/or availability	9	(13.4)	[50,52,53,60–65]
Reimbursement	1	(1.5)	[62]
<b>Others</b>	<b>3</b>	<b>(4.59)</b>	<b>[57,66,67]</b>

\* Some studies investigated more than one outcome and therefore the numbers of outcomes exceeds the number of studies.

peptides (e.g. BNP, NT-proBNP), while the remaining six studies (42.9%) included POCT measurements of troponin.

#### Research focus and studied outcomes in primary studies on the use of POCT in outpatient care in Germany

Considering the primary studies, we identified nine pre-clinical studies (9/67, 13.4%) which provide data on the technical development of novel POCT (Table 3); among these six studies on POCT targeted for outpatient testing of infectious diseases, such as respiratory tract infections and malaria. However, these studies do not provide any data on the clinical utility of POCTs. Our systematic literature search shows that the majority (40/67, 56.7%) of primary research studies in Germany focus on the analytical and diagnostic performance of POCTs. A typical diagnostic accuracy study includes

testing of target patient samples using the POCT and the established reference method (gold standard) which defines the “true” disease status for each patient. By using predefined diagnostic thresholds for the POCT, the diagnostic accuracy can be calculated in comparison to the reference method. Most of these studies found that the diagnostic performance of POCT is sufficient for clinical routine use and is often not significantly inferior to established laboratory tests.

Going beyond test accuracy, eleven studies (16.4%) presented data on implementation aspects of POCT in outpatient care, including quality assurance and user training. Nine studies (13.4%) focused on data on the frequency of use and availability of POCT in German outpatient care.

Importantly, our results show that only few POCT primary research studies provide data on the therapeutic impact (4/67, 5.9%)

and clinical effectiveness (2/67, 3.0%). Among those, Deichmann et al. [31] and Jennings et al. [64] reported results from the same non-randomized interventional study and found that the use of point-of-care influenza testing decreased the number of antibiotic prescriptions and impacts the initiation of antiviral therapy compared to the control group (no influenza POCT) in outpatient pediatric practices. Two observational studies in emergency medical services reported that POCT measurements of vitality markers (such as pH, K<sup>+</sup>, lactate, glucose) impacts acute therapeutic interventions [55,56], but did not result in statistical significant differences in health outcomes between patients with preclinical vs. patients without preclinical POCT measurements [55]. One RCT comparing POCT measurement of BNP vs. standard assessment without BNP did not find differences in health outcomes of patients presenting with dyspnea in primary care practices in Switzerland and Germany [28]. However, BNP-POCT decreased the need for further diagnostic procedures and accelerated the initiation of the appropriate treatment.

In addition to therapeutic impact and clinical effectiveness, economic aspects (e.g. cost effectiveness and reimbursement) as well as user and patient perspectives are key elements for successful implementation of POCT in routine outpatient healthcare. However, our literature search shows that these endpoints are rarely addressed in German primary research studies (Table 2).

#### *German clinical recommendations and consensus papers with focus on the use of POCT in outpatient care*

Among the seven clinical recommendations / position papers, three articles summarize requirements for measurement quality and quality assurance of POCT systems in the measurement of blood glucose for diagnosing diabetes manifested in pregnancy [92,93,122]. In 2009, the *POCT Working Group of the German Society for Clinical Chemistry and Laboratory Medicine* published suggestions on standardized POCT measurements of blood glucose [76]. One joint position paper on POCT for sexual transmitted diseases (STI) published in 2017 emphasizes the potential of POC-testing to lower the barrier of testing and improving access to testing [88]. This position paper concludes that POCT for HIV, HCV and syphilis are well suited for POC-testing. In contrast, sufficient diagnostic accuracy for detection of *C. trachomatis* and *N. gonorrhoeae* can only be achieved by PCR-based POCTs. In a clinical recommendation, Betz et al. [19] describe the diagnostic value and routine use of preclinical POC-testing of blood gas analysis in emergency care. In a clinical guideline on patient self-management of oral anticoagulation from 2009, the authors highlight the diagnostic potential of patient self-testing of oral anticoagulation as it improves therapies and decreases the risk for thromboembolic events and bleedings [26]. However, this guideline was not updated and therefore may not reflect the current state of scientific evidence.

## Discussion


Given their low turnaround time and user-friendliness, POC laboratory tests offer great potential in the management of patients in outpatient care, including primary care practices or outpatient emergency care. In order to ensure an evidence-based use of POCT in German outpatient care, robust scientific evidence is needed, preferably derived from studies conducted in German outpatient healthcare facilities to increase the external validity. Our scoping review identified and analysed 117 articles on POCT use in outpatient care published by German researchers.

A systemic overview on international POCTs studies concluded that evidence generation tends to focus on accuracy and overlooks other test attributes such as impact, implementation and cost-

effectiveness [7]. In line with these findings, our results show that also most German primary research studies focused on the diagnostic accuracy of POCTs, while evidence for other critical aspects, such as therapeutic impact, (comparative) clinical and cost effectiveness as well as user and patient perspectives is relatively rare. Even less evidence is available for the feasibility of POCT in routine outpatient healthcare and the organisational consequences of POCT use, such as improved patient flows or optimized practice routines. Importantly, rapid and sufficient diagnostic performance of POCT does not necessarily translate into improved patient outcomes [134] and results from diagnostic accuracy studies provide limited or no evidence on the therapeutic impact or broader implications of POCT use in routine healthcare practice.

According to Horvath et al. [135] the evaluation of in-vitro diagnostic tests, including POCTs, encompasses (i) analytical performance (e.g. precision), (ii) diagnostic performance (e.g. sensitivity, specificity), (iii) (comparative) clinical effectiveness (improvement of patient outcomes), (iv) cost-effectiveness and (v) broader impact, such as acceptance and organizational consequences. In addition, Fryback and Thornbury [136] defined the impact of diagnostics on diagnostic thinking and therapy decisions as further relevant endpoints that go beyond analytical and diagnostic performance. Based on these studies, our own research activity and this literature review, we define six domains of endpoints that should be addressed in the evaluation of a given POCT to comprehensively understand its potential benefits in outpatient care: (i) diagnostic performance, (ii) clinical performance, (iii) time and costs, (iv) impact on clinical routines / processes, (v) perspectives of medical professionals and patients, and (vi) broader aspects (see Figure 2). Based on our results from German POCT studies, POCTs for outpatient care are typically well characterized in their diagnostic performance (domain i) but evidence for all other endpoint domains is usually lacking. In accordance with the principles of evidence-based medicine, the effectiveness of POCT use in outpatient care should be assessed in interventional studies, preferably in randomized controlled clinical trials (RCTs), which are the gold standard in clinical research [137–139]. For POCT interventions in outpatient practices, cluster-randomised interventional studies may be preferable over patient-randomised trials as test operators cannot be trained / untrained between individual patients or outcomes are collected on the level of physicians (e.g. prescription behaviour). However, RCTs are often time and resource consuming, especially in the decentralised outpatient care setting. Therefore, other interventional study designs, such as non-controlled studies (e.g. pre-post studies) or non-randomized controlled trials as well implementation studies [140], may also offer valuable data on the effectiveness of POCT when RCTs are not feasible.

Importantly, as indicated by our spectrum of different research endpoints, the added value of POCT (or any other diagnostic procedure) should not be solely judged by their impact on patient health outcomes as it is the case in therapeutic interventions. Given their upstream role in patient management and the context of all other factors influencing patient outcomes, the independent effect (if any) of POCT to health outcomes may be small and therefore very large sample sizes may be required in appropriate clinical trials [141]. Even if POCT do not improve patient health outcomes compared to standard (laboratory) diagnostic procedures, their routine application in outpatient care may be beneficial as they might improve patient flows, therapeutic decisions, communication with patients, patient satisfaction and can be associated with time and cost savings in primary care. For example, there is robust evidence that POCT measurements of C-reactive protein (CRP) result in decreased prescriptions of antibiotics in primary care [142,143] and are cost-effective [144,145]. Although these studies show that patient health outcomes are not improved by CRP-POCTs, their use



**Figure 2.** Research endpoints for the evaluation of POCT used in outpatient and adapted and modified from Verbakel et al. [7], Horvath et al. [135] and Fryback and Thornbury [136].

is recommended in clinical guidelines to reduce diagnostic uncertainty and to aid prescribing decisions [146,147].

Depending on the diagnostic goal, target disease and user requirements, different POCT require various evidence on their potential clinical value for routine application [141]. A recent systematic review on POCTs in primary care showed that POCT evaluation studies do often not investigate aspects that are relevant for general physicians in the decision to implement a POCT in practice [148]. It is therefore desirable to involve outpatient medical professionals (physicians and medical assistants) in the definition of relevant clinical endpoints. Moreover, the involvement of patients has recently gained significance as their perspectives provide valuable input in the planning and interpretation of clinical studies [149]. The evaluation of POCT use may include both quantitative clinical studies as well as qualitative approaches which can provide valuable data on attitudes, implementation barriers and acceptance among users (medical professionals) and patients.

In addition to relevant endpoints, it is also important that studies on POCT use are conducted in the target setting in order to provide robust data that are representative to the “real-life” outpatient care context. Recruiting outpatient practices for research projects often is challenging [150] since resources and, in some cases research interest, are limited among outpatient physicians. Consequently, many studies on healthcare intervention, including in-vitro diagnostics, are carried out at university hospitals which have dedicated research personnel and resources. However, patient characteristics, medical infrastructure and legal obligations are fundamentally different in the hospital setting compared to outpatient settings. In order to recruit outpatient practices for research projects, research approaches should be tailored to the context of

outpatient care settings, which includes the involvement of outpatient medical professionals in all steps of the research project, definition of endpoint relevant for outpatient physicians and may also include appropriate financial compensation.

Importantly, our scoping review indicates that there might be a publication bias in primary POCT research studies since only four studies interpreted the obtained data as not favorable for the POCT in question. As known for decades, publication bias is a serious problem in clinical research [151–153] and also has been described for diagnostic accuracy studies [132,133]. It is therefore important to implement strategies to prevent publication bias towards favourable results, such mandatory publication of study protocols or journal policies to accept and publish “negative results”.

#### Strengths and limitations

To our knowledge, no scoping review on research activity on POCT use in German outpatient care has been conducted yet. Based on 117 included scientific articles, our study provides a comprehensive overview on publication types, studied POCT and diseases as well as outcomes addressed in recent POCT research in Germany. However, our scoping review has some limitations. Firstly, we designed a systematic literature search to specifically identify POCT articles with focus on outpatient care in Germany. However, it might be possible that our search did not cover all articles on potentially relevant POCT research, especially in cases where studies did not specifically mention outpatient care settings. This is most likely true for technical development (“proof-of-principle”) studies that do not specify any particular clinical setting. Secondly, grey literature, such as academic theses, may not be fully covered

with our search strategy and used electronic databases. Despite the potentially limited sensitivity of our systematic literature search, our scoping review is a representative snapshot of the German research activity on POCT use in outpatient care.

## Conclusion

There is considerable research activity on POCT use in German primary care. The majority of primary research studies focuses on the diagnostic performance of POCTs. Similar to international POCT studies, evidence beyond diagnostic accuracy remains scarce, such as impact on therapeutic decisions and practice routines / processes, clinical effectiveness, and user and patient perspectives. We defined six research domains of endpoints that should be addressed in POCT evaluation to comprehensively understand potential benefits and challenges of POCT use in primary care.

## Data statement

All data are available on reasonable request from the authors.

## Funding

This work was supported by the German Federal Ministry of Education and Research [InfectoGnostics Research Campus Jena, grant number 13GW0461]. The funding source had no influence in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

## Acknowledgement

We thank Anne Stein and Sophia Wiegand for her support in literature organization.

## Conflict of interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Anni Matthes, Robby Markwart report financial support was provided by German Federal Ministry of Education and Research.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.zefq.2022.06.002>.

## References

- [1] Junker R, Schlebusch H, Lappa PB. Point-of-care testing in hospitals and primary care. *Dtsch Arztebl Int* 2010;107(33):561–7.
- [2] Lappa PB et al. Point-of-care testing (POCT): Current techniques and future perspectives. *Trends Analys Chem* 2011;30(6):887–98.
- [3] Market Data Forecast, Europe Point of Care (POC) Diagnostics/Testing Market Research Report – Segmented By Product, End-User, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Size, Share, Trends, Growth Opportunities Assessment, Industry Forecast | 2021 to 2026. 2021, Market Data Forecast.
- [4] Frese T et al. Use of point-of-care tests among general practitioners: a cross-sectional study in Saxony, Germany. *Rural Remote Health* 2016;16(1):352.
- [5] Howick J et al. Current and future use of point-of-care tests in primary care: an international survey in Australia, Belgium, The Netherlands, the UK and the USA. *BMJ Open* 2014;4(8):e005611.
- [6] Jones CH et al. Primary care clinicians' attitudes towards point-of-care blood testing: a systematic review of qualitative studies. *BMC Fam Pract* 2013;14:117.
- [7] Verbaek JY et al. Common evidence gaps in point-of-care diagnostic test evaluation: a review of horizon scan reports. *BMJ Open* 2017;7(9):e015760.
- [8] Pocock S et al. International differences in treatment effect: do they really exist and why? *Eur Heart J* 2013;34(24):1846–52.
- [9] Vieta E et al. Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. *Int J Neuropsychopharmacol* 2011;14(8):1017–27.
- [10] Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *Int J Soc Res Methodol* 2005;8(1):19–32.
- [11] Tricco AC et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med* 2018;169(7):467–73.
- [12] von Elm E, Schreiber G, Haupt CC. Methodische Anleitung für Scoping Reviews (JBI-Methodologie). *Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen* 2019;143:1–7.
- [13] Munn Z et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. *BMC Med Res Method* 2018;18(1):143.
- [14] Ouzzani M et al. Rayyan—a web and mobile app for systematic reviews. *System Rev* 2016;5(1):210.
- [15] Barabas N, Bietenbeck A. Application guide: Training of professional users of devices for near-patient testing. *LaboratoriumsMedizin* 2017;41(5):215–8.
- [16] Baumstark A et al. Bewertung der Systemgenauigkeit von Point-of-Care-Geräten für die Blutglukosebestimmung: Ein Vergleich zwischen einem Blutglukose-Messsystem für die Patientenselbstkontrolle mit 6 Geräten für den professionellen Gebrauch. *Diabetologie Stoffwechsel* 2014;9: P117.
- [17] Baumstark A et al. Measurement accuracy of two professional-use systems for point-of-care testing of blood glucose. *Clin Chem Lab Med* 2019.
- [18] Becker J, Diel R. Screening for Methicillin-resistant *Staphylococcus aureus* in a residence home for elderly in Germany. *J Occupat Med Toxicol* 2017;12(1).
- [19] Betz S, Plöger B, Kill C. D – Point of Care – Die präklinische Blutgasanalyse als diagnostisches Tool. *Notfall + Rettungsmedizin* 2017;20(2):132–40.
- [20] Bingisser R et al. Measurement of natriuretic peptides at the point of care in the emergency and ambulatory setting: Current status and future perspectives. *Am Heart J* 2013;166(4):614–621.e1.
- [21] Blank WA, Schmidt R, Schneider A. Use of troponin T testing in family practice: Use and benefit of troponin T testing based on a census of Bavarian family doctors. *Zeitschrift für Allgemeinmedizin* 2009;85(10):418–22.
- [22] Blankenstein T, et al. Point-of-care (POC) diagnosis of bacterial vaginosis (BV) using VGTest™ ion mobility spectrometry (IMS) in a routine ambulatory care gynecology clinic. *Arch Gynecol Obstet* 292(2): 355–62.
- [23] Boldt K. Vergleichende Untersuchung der prognostischen Relevanz von BNP, NT-proBNP, hsCRP und TNF- $\alpha$  bei Patienten mit klinisch-anamnestischem Verdacht auf das Vorliegen einer Herzinsuffizienz in der Hausarztpraxis: Follow-up-Untersuchung zur Grundstudie zur Objektivierung der kardiovaskulären Dysfunktion im ambulanten und hausärztlichen Bereich mittels handgehaltener Echokardiographie und dem BNP-Schnelltest (Handheld-BNP-Studie) Prognostic utility of BNP, NT-proBNP, hsCRP and TNF- $\alpha$  in the assessment of patients with suspected heart failure in primary care. The Handheld-BNP-Study 2011.
- [24] Borensztajn D et al. Diversity in the emergency care for febrile children in Europe: a questionnaire study. *BMJ Paediatrics Open* 2019;3(1):e000456.
- [25] Braun S, Spannagl M, Völker H. Patient self-testing and self-management of oral anticoagulation. *Anal Bioanal Chem* 2009;393(5):1463–71.
- [26] Braun S et al. Update of guidelines for patient self-management of oral anticoagulation. *Dtsch Med Wochenschr* 2009;134(14):695–700.
- [27] Brumberg J. In: Wahl HG, editor. *Untersuchungen zur Gerätetoleranz und Changerabilität von Point-of-care-Testing Blutzuckermessgeräten*. Philipps-Universität Marburg; 2015.
- [28] Burri E et al. B-type natriuretic peptide in the evaluation and management of dyspnoea in primary care. *J Intern Med* 2012;272(5):504–13.
- [29] Busse J. *Dabigatran, Rivaroxaban, Apixaban, Argatroban und Fondaparinux und ihre Effekte auf Point-of-Care-sowie Plättchenfunktionstests*. Medizinische Fakultät. Bochum: Ruhr-Universität Bochum; 2020.
- [30] Clouth A et al. The point-of-care-diagnostic with C-reactive protein in the routine. *Clin Exper Med Lett* 2009;50(2):71–4.
- [31] Deichmann KA, Enk C, Hribar I. Impact of rapid influenza testing on physician prescribing behaviour. Results from a prospective study in German pediatric centers during the influenza season 2006/2007. *Pädiatrische Praxis* 2009;73(2):313–20.
- [32] Dempfle CE et al. Sensitivity and specificity of a quantitative point of care D-dimer assay using heparinized whole blood, in patients with clinically suspected deep vein thrombosis. *Thromb Haemost* 2006;96(1):79–83.
- [33] Diel R, Nienhaus A. Cost-benefit analysis of real-time influenza testing for patients in german emergency rooms. *Int J Environ Res Public Health* 2019;16(13).
- [34] Dolscheid-Pommerich RC et al. Evaluation of the appropriate time period between sampling and analyzing for automated urinalysis. *Biochem Med* 2016;26(1):82–9.
- [35] Eggers M, Enders M, Terletskaia-Ladwig E. Evaluation of the becton dickinson rapid influenza diagnostic tests in outpatients in Germany during seven influenza seasons. *PLoS ONE* 2015;10(5).
- [36] Elliott T et al. Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. *J Int AIDS Soc* 2019;22(12).
- [37] Erbach M et al. Interferences and limitations in blood glucose self-testing: An overview of the current knowledge. *J Diabetes Sci Technol* 2016;10(5):1161–8.

- [38] Erk A. Point-of-Care Bestimmung der Prothrombinzeit mittels CoaguChek® XS bei präklinischen Notfalleinsätzen. Medizinische Fakultät Heidelberg. Universitätsklinik für Anästhesiologie. Heidelberg, Germany: Ruprecht-Karls-Universität Heidelberg; 2016.
- [39] Exner V, et al., Prescribing of antibiotics for respiratory tract infections in German outpatient pediatric care Results of a survey of pediatricians and general practitioners. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 63(10): 1231–40.
- [40] Figueroa M et al. Polyethylene glycol-mediated blocking and monolayer morphology of an electrochemical aptasensor for malaria biomarker detection in human serum. Bioelectrochem (Amsterdam, Netherlands) 2020;136:107589.
- [41] Freckmann G. HbA1c-POC systems for therapy control and diagnostics of diabetes: Is quality and quality control sufficient? LaboratoriumsMedizin 2017;41(5):263–7.
- [42] Freckmann G et al. System accuracy evaluation of systems for point-of-care testing of blood glucose: A comparison of a patient-use system with six professional-use systems. Clin Chem Lab Med 2014;52(7):1079–86.
- [43] Freiherr Von Recum J. Universitätsbibliothek Der FUB. Akutdiagnostik im notfallmedizinischen Kontext; 2020.
- [44] Frese T, et al., Use of point-of-care tests among general practitioners: a cross-sectional study in Saxony, Germany. Rural Remote Health 16(1): 3552.
- [45] Fritzenwanker M et al. Modern diagnostic methods for urinary tract infections. Expert Review of Anti-Infective Therapy 2016;14(11):1047–63.
- [46] Fröde D. Universitätsbibliothek B, Dübels S. Rekombinante Antikörper für die Point-of-care-Diagnostik von CRP; 2012.
- [47] Gal M et al. Matching diagnostics development to clinical need: Target product profile development for a point of care test for community-acquired lower respiratory tract infection. PLoS ONE 2018;13(8):e0200531.
- [48] Gauglitz G, Lupp PB. Patientennahe Labordiagnostik. Point-of-Care-Testing. Chemie in unserer Zeit 2009;43(5):308–18.
- [49] Gebauer A, Schmidt S, Hoffmann W. Status and perspective of lab-on-a-chip systems for common diseases: A systematic review from 2003 to 2013. Personal Med 2016;13(1):71–91.
- [50] Gildorf A et al. Highly variable use of diagnostic methods for sexually transmitted infections-results of a nationwide survey, Germany. BMC Infect Dis 2005;10:98.
- [51] Goncalves A, et al. Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report. J Infect Dis 217(7): 1060–8.
- [52] Görlinger K et al. Messung der Thrombozytenfunktion mit Point-of-Care-Methoden. Herz 2008;33(4):297–305.
- [53] Greaves RF et al. Key questions about the future of laboratory medicine in the next decade of the 21st century: A report from the IFCC-Emerging Technologies Division. Clin Chim Acta 2019;495:570–89.
- [54] Greenaway C et al. The effectiveness and cost-effectiveness of hepatitis c screening for migrants in the EU/EEA: A systematic review. Int J Environ Res Public Health 2018;15(9).
- [55] Grübl T. Praktische Point-of-Care-Diagnostik bei Reanimation: Wie relevant sind erste Laborwerte für den Notarzt? 2019.
- [56] Hahn B et al. Mobiles Notfall-Labor in der präklinischen Notfallmedizin. Der Notarzt 2016;32(03):117–21.
- [57] Halimeh S et al. Multiplate® whole blood impedance point of care aggregometry: Preliminary reference values in healthy infants, children and adolescents. Klin Padiatr 2010;222(3):158–63.
- [58] Harenberg J, et al. Novel methods for assessing oral direct factor xa and thrombin inhibitors: Use of point-of-care testing and urine samples. Semin Thromb Hemost 2013;39(1):66–71.
- [59] Harenberg J, Kraemer R. PL-23 measurement of the new anticoagulants. Thromb Res 2012;129:S106–13.
- [60] Hasslacher C, Kulozik F. Hämatokrit-induzierte Interferenz bei Point-of-Care Geräten zur Blutzuckermessung. Diabetologie und Stoffwechsel 2014;9.
- [61] Hays JP, et al. The successful uptake and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing requires a complex 'mix-and-match' implementation package. Eur J Clin Microbiol Infect Dis. 38 (6): 1015–22.
- [62] Hermanns N et al. Überprüfung der Messgenauigkeit des „Point of Care“ Blutzuckermesssystems smart LAB®. Diabetologie und Stoffwechsel 2009;4, P\_294.
- [63] Horák J. Microfluidic Immunosensor for Point-of-care Diagnostics: Microfluidischer Immunosensor Für Patientennahe Diagnostik. Technical Faculty, Department of Microsystems Engineering. Freiburg, Germany: University of Freiburg; 2013.
- [64] Jennings LC, et al. Effect of rapid influenza testing on the clinical management of paediatric influenza. Influenza Other Respir Viruses 3(3): 91–8.
- [65] Jung E, et al. Combination of channel- and droplet-based microfluidics for complex PoC devices. Fraunhofer IZM, Gustav-Meyer-Allee 25, 13355 Berlin, Germany Technical University of Berlin, FSP-TdM, Gustav-Meyer-Allee 25, 13355 Berlin, Germany CNRS FEMTO Innovation, 32 Avenue Observatoire, F-2500 Besançon, France, 29 May 2012 through 1 June 2012 San Diego, CA.
- [66] Jungbauer C et al. Analytical and clinical validation of a point-of-care cardiac troponin T test with an improved detection limit. Clin Lab 2017;63 (4):633–45.
- [67] Jungbauer CG et al. Equal performance of novel N-terminal proBNP (Cardiac proBNP®) and established BNP (Triage BNP®) point-of-care tests. Biomarkers Med 2012;6(6):789–96.
- [68] Junker R, Schlebusch H, Lupp PB. Point-of-care testing in hospitals and primary care. Dtsch Arztbl Int 107(33): 561–7.
- [69] Kachler M, Maschek C. Organizational challenges in the management of point-of-care diagnostics in healthcare facilities. J Lab Med 2020;44.
- [70] Kaman WE, Andrinopoulou ER, Hays JP. Perceptions of point-of-care infectious disease testing among European medical personnel, point-of-care test kit manufacturers, and the general public. Patient Prefer Adherence 2013;7:559–77.
- [71] Kampfenkel T. Machbarkeit und Nutzen von einem 12-Kanal-EKG und einer "Point-of-care" Bestimmung von Myokardnekroseparametern in der prähospitalen Diagnostik von Patienten mit Verdacht auf ein akutes Koronarsyndrom. 2009.
- [72] Karl I, Kaduszkiewicz H. Labor statt Klinik? Bestimmung des CRP bei Atemwegsinfekten in der Hausarztpraxis. Z Allg Med 2018;94:276–81.
- [73] Klamp T. Ein schnelles Bead-basiertes und bildgebendes Verfahren zur Quantifizierung von Nukleinäsuren für die Integration in Lab-on-a-Chip-basierten Point-of-Care-Testing-Systemen.
- [74] Klein FK et al. Analytic Issues in the Diagnosis of GDM - Comparison of 6 Analytical Methods for Plasma Glucose. Diabetologie und Stoffwechsel 2016;11(2):155–62.
- [75] Köchling A, et al. Reduction of antibiotic prescriptions for acute respiratory tract infections in primary care: a systematic review. Implement Sci 13(1): 47.
- [76] Koschinsky FdAPT et al. Verbesserung der Therapiesicherheit durch eine einheitliche Kalibration von POCT-Glukose-Messgeräten auf Plasma Stellungnahme der Arbeitsgruppe POCT der Deutschen Vereinten Gesellschaft für Klinische Chemie und Laboratoriumsmedizin / Improvement of therapeutic safety through standardized plasma calibration of blood glucose test systems at the point-of-care Statement of the POCT Working Group of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL). LaboratoriumsMedizin 2009;33(6):349–52.
- [77] Koschinsky T. Screening and diagnostic procedures for gestational diabetes mellitus. Requirements of blood glucose measurement. Diabetologe 2012;8 (8):632–8.
- [78] Kunze M et al. Interleukin-6-Schnelltest im Vaginalsekret bei Schwangeren mit vorzeitiger Wehenaktivität. Zeitschrift für Geburtshilfe und Neonatologie 2009;213, p. PO\_G\_09\_02.
- [79] Kutz A et al. Comparison between B-R-A-H-M-S PCT direct, a new sensitive point-of-care testing device for rapid quantification of procalcitonin in emergency department patients and established reference methods - A prospective multinational trial. Clin Chem Lab Med 2016;54(4):577–84.
- [80] Lemke C, Matthaei S. Präzision und Richtigkeit der neuesten Version des Point of Care (POC) Gerätes A1CNow+. Diabetologie und Stoffwechsel 2009;4, p. P\_293.
- [81] Litwin AH, et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study. J Viral Hepat 26(9): 1094–104.
- [82] Lorenz K, et al. Evaluation of a novel point-of-care test for active matrix metalloproteinase-8: agreement between qualitative and quantitative measurements and relation to periodontal inflammation. J Periodontal Res 52 (2): 277–84.
- [83] Lupp PB et al. Clinically relevant analytical techniques, organizational concepts for application and future perspectives of point-of-care testing. Biotechnol Adv 2016;34(3):139–60.
- [84] Lupp PB, Schlebusch H. Analytical methods and clinical applications of point-of-care testing - A survey. Medizinische Welt 2013;64(1):5–11.
- [85] Maß S et al. Diagnostics and therapy of sore throat patients presenting in primary care: An observational study. Zeitschrift für Allgemeinmedizin 2016;92(6):269–75.
- [86] MacLean E et al. Advances in molecular diagnosis of tuberculosis. J Clin Microbiol 2020;58(10).
- [87] Meyer T, Buder S. The laboratory diagnosis of neisseria gonorrhoeae: Current testing and future demands. Pathogens 2020;9(2).
- [88] Meyer T et al. Schnelltest-Diagnostik sexuell übertragbarer Infektionen in niedrigschwelligen Einrichtungen: Gemeinsame Stellungnahme des RKI, PEI und der DSTIG. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2017;60(2):245–54.
- [89] Mitsakakis K, et al. Diagnostic tools for tackling febrile illness and enhancing patient management. Microelectron Eng 201: 26–59.
- [90] Mitsakakis K, et al. Challenges in identifying antibiotic resistance targets for point-of-care diagnostics in general practice. Future Microbiol 13(10): 1157–64.
- [91] Morbach C, et al. Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. Clin Res Cardiol 107(2): 95–107.
- [92] Neumaier M et al. Aktualisierte Anforderungen an die Messqualität und Qualitätssicherung (QS) von Point-of-Care-Testing (POCT)-Blutglukose-Messsystemen mit Unit-use Reagenzien, die für die Erstdiagnostik eines manifesten Diabetes in der Schwangerschaft oder eines Gestationsdiabetes mellitus (GDM) gemäß der GDM-Leitlinie der Deutschen Diabetes-Gesellschaft (DDG) geeignet sind. LaboratoriumsMedizin 2015;39(4):183–6.
- [93] Neumaier M et al. Updated Requirements for Measurement Quality and Quality Assurance of Point-Of-Care Testing (POCT) - Blood Glucose Measurement Systems with Unit-Use Reagents Suitable for the Initial Diagnosis of Diabetes Manifested in Pregnancy or Gestational Diabetes Mellitus (GDM) According to the GDM Guideline of the German Diabetes Association (DDG). Diabetologie und Stoffwechsel 2015;10(4):E1–3.

- [94] O'Sullivan S et al. Developments in transduction, connectivity and AI/machine learning for point-of-care testing. *Sensors (Switzerland)* 2019;19(8).
- [95] Okeke IN et al. Diagnostics as essential tools for containing antibacterial resistance. *Drug Resist Updates* 2011;14(2):95–106.
- [96] Palacio M et al. Meta-analysis of studies on biochemical marker tests for the diagnosis of premature rupture of membranes: Comparison of performance indexes. *BMC Pregnancy Childbirth* 2014;14(1).
- [97] Patzer KH et al. Implementation of HbA1c Point of Care Testing in 3 German Medical Practices: Impact on Workflow and Physician, Staff, and Patient Satisfaction. *J Diabetes Sci Technol* 2018;12(3):687–94.
- [98] Peetz D, Hafner G, Lackner KJ. Near-patient testing of natriuretic peptides. *LaboratoriumsMedizin* 2005;29(4):219–28.
- [99] Pfab T et al. Rapid immunochromatographic strip test for the detection of albuminuria and brief literature review on albuminuria screening. *Eur J Med Res* 2006;11(1):3–6.
- [100] Pfäfflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). *Anal Bioanal Chem* 2009;393(5):1473–80.
- [101] Pleus S, et al. Bewertung der Messgenauigkeit von zwei Point-of-Care-Testing-Blutglukosemesssystemen für den professionellen Gebrauch. 2018, Georg Thieme Verlag KG: Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany M4 - Citavi. p. P 194.
- [102] Reinitz RR. Rapid streptococcal antigen detection tests. *LaboratoriumsMedizin* 2007;31(6):280–93.
- [103] Reis C, Universität S. Magneto-hydrodynamische Fokussierung: ein neues Verfahren für die Point of Care Diagnostik. Stuttgart: Fraunhofer Verlag; 2018.
- [104] Risch L, Senn O. *Symptom based approaches in point of care laboratory testing*. *Ther Umsch*. 72(2): 105–12.
- [105] Ritzi-Lehnert M. *Development of chip-compatible sample preparation for diagnosis of infectious diseases*. *Expert Rev Mol Diagn* 12(2): 189–206.
- [106] Rizos T et al. Fast point-of-care coagulometer guided reversal of oral anticoagulation at the bedside hastens management of acute subdural hemorrhage. *Neurocrit Care* 2010;13(3):321–5.
- [107] Rübenhagen R, Dangers M. Evaluation of a novel point-of-care test for the rapid semi-quantitative detection of allergen-specific immunoglobulin E. *J Immunoassay Immunochem* 2017;38(5):538–54.
- [108] Schafberger ASK, Sporleder U, Taubert S. DeutscheAIDS-Hilfe, *Externe Qualitäts sicherung für den Syphilis-Schnelltest: A 78*, in Deutscher STI-Kongress. 2014: Berlin, Germany.
- [109] Schäfer M et al. Diagnostic equivalence of an N-terminal pro-brain natriuretic peptide point-of-care test to the laboratory method in patients with heart failure and in reference populations. *Point of Care* 2010;9(2):91–7.
- [110] Schito M et al. Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis. *J Infect Dis* 2012;205:S169–80.
- [111] Schmalenberg M et al. Magnetic bead fluorescent immunoassay for the rapid detection of the novel inflammation marker YKL40 at the point-of-care. *J Immunol Methods* 2015;427:36–41.
- [112] Schnell O, Crocker JB, Weng J. Impact of HbA1c Testing at Point of Care on Diabetes Management. *J Diabetes Sci Technol* 2017;11(3):611–7.
- [113] Schols AMR, et al. International definition of a point-of-care test in family practice: a modified e-Delphi procedure. *Family Practice* 35(4): 475–80.
- [114] Schweiger B. Influenza rapid tests – Advantages and limitations. *LaboratoriumsMedizin* 2006;30(4):219–25.
- [115] Siebenhofer A et al. Self-management of oral anticoagulation. *Deutsches Ärzteblatt. International* 2014;111(6), p. 83–91+10.
- [116] Slagman A et al. Diagnostic performance of a high-sensitive troponin T assay and a troponin T point of care assay in the clinical routine of an Emergency Department: A clinical cohort study. *Int J Cardiol* 2017;230:454–60.
- [117] Spitzenberger F. Charakteristika der neuen EU-Verordnung über In-vitro-Diagnostika und Auswirkungen auf POCT und medizinische Laboratorien. *LaboratoriumsMedizin* 2017;41(5):257–62.
- [118] Stahl LS, et al. Der Quantum Blue® (Bühlmann Laboratories AG) Schnelltest erkennt erhöhte Calprotectin-Werte im Speichel und Serum von Patienten mit Peritonitis-Abszess. 2019, Georg Thieme Verlag KG: Klinik für HNO, Universitätsklinikum Münster, Münster Institut für Immunologie, Universitätsklinikum Münster, Münster M4 - Citavi. p. 10862.
- [119] Stein J. *Schnelltest zum Nachweis einer Helicobacter pylori-Infektion bei Kindern*, in Medizinischen Fakultät, Klinische Medizin. Homburg/Saar: Universität des Saarlandes; 2007.
- [120] Stürenburg E, Junker R. Point-of-care testing in microbiology - The advantages and disadvantages of immunochromatographic test strips. *Deutsches Ärzteblatt* 2009;106(4):48–54.
- [121] Tangermann P et al. Low Sensitivity of Simtomax Point of Care Test in Detection of Celiac Disease in a Prospective Multicenter Study. *Clin Gastroenterol Hepatol* 2019;17(9):1780–1787.e5.
- [122] Thiery J et al. Anforderungen an die Messqualität und Qualitätssicherung (QS) von Point-of-Care-Testing(POCT)-Blutglukose-Messsystemen, die für das Screening und die Diagnose eines Gestationsdiabetes mellitus (GDM) gemäß der GDM-Leitlinie der Deutschen Diabetes-Gesellschaft (DDG) geeignet sind. *Diabetologie und Stoffwechsel* 2013;8(3):195–7.
- [123] Toepfner N et al. Impact of technical training on rapid antigen detection tests (RADT) in group A streptococcal tonsillopharyngitis. *Eur J Clin Microbiol Infect Dis* 2013;32(5):609–11.
- [124] Topf HG et al. Closing the gap - Detection of clinically relevant von Willebrand disease in emergency settings through an improved algorithm based on rotational Thromboelastometry 11 Medical and Health Sciences 1103 Clinical Sciences 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology. *BMC Anesthesiol* 2019;19(1).
- [125] van Oordt TSO, Mark D, Kosse D, Roth G, Achazi K, Patel P, et al. A Functional Blister-Pack LabDisk System for Point of Care Testing, in *Deutsche Gesellschaft für Hygiene und Mikrobiologie*; 2012.
- [126] Weber K, et al. Partikel- und chipbasierte Anreicherung von Bakterien für einen Point-of-Care-Nachweis; 2017.
- [127] Weitzel T et al. Evaluation of a new point-of-care test for influenza A and B virus in travellers with influenza-like symptoms. *Clin Microbiol Infect* 2007;13(7):665–9.
- [128] Wiesenreiter J. Evaluierung des concile Omega 100 Point-of-Care-Systems zur Bestimmung des totalen und freien prostataspezifischen Antigens im Serum im Hinblick .... Medizinische Fakultät. Tübingen: Eberhard Karls Universität zu Tübingen; 2017.
- [129] Wratil PR et al. Comparative multi-assay evaluation of Determine™ HIV-1/2 Ag/Ab Combo rapid diagnostic tests in acute and chronic HIV infection. *Med Microbiol Immunol* 2020;209(2):139–50.
- [130] Zugck C et al. Multicentre evaluation of a new point-of-care test for the determination of NT-proBNP in whole blood. *Clin Chem Lab Med* 2006;44 (10):1269–77.
- [131] Zumla A et al. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections-needs, advances, and future prospects. *Lancet Infect Dis* 2014;14(11):1123–35.
- [132] Treanor L et al. Publication bias in diagnostic imaging: conference abstracts with positive conclusions are more likely to be published. *Eur Radiol* 2020;30 (5):2964–72.
- [133] Vollgraff Heidweiller-Schreurs CA et al. Publication bias may exist among prognostic accuracy studies of middle cerebral artery Doppler ultrasound. *J Clin Epidemiol* 2019;116:1–8.
- [134] Gerke O, Hoilund-Carlsen PF, Vach W. Analyzing paired diagnostic studies by estimating the expected benefit. *Biom J* 2015;57(3):395–409.
- [135] Horvath AR et al. From biomarkers to medical tests: the changing landscape of test evaluation. *Clin Chim Acta* 2014;427:49–57.
- [136] Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. *Med Decis Making* 1991;11(2):88–94.
- [137] Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: Study design: randomised controlled trials. *BJOG* 2018;125(13):1716. <https://doi.org/10.1111/1471-0528.15199>. Epub 2018 Jun 19. PMID: 29916205; PMCID: PMC6235704.
- [138] Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. *J Intern Med* 2003;254 (2):105–13.
- [139] Grossman J, Mackenzie FJ. The randomized controlled trial: gold standard, or merely standard? *Perspect Biol Med* 2005;48(4):516–34.
- [140] Pinnock H et al. Standards for Reporting Implementation Studies (StARI) Statement. *BMJ* 2017;356:i6795.
- [141] Van den Bruij A et al. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. *J Clin Epidemiol* 2007;60(11):1116–22.
- [142] Abenius R et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. *Cochrane Database Syst Rev* 2014;11, p. Cd010130.
- [143] Verbakel JV et al. Impact of point-of-care C reactive protein in ambulatory care: a systematic review and meta-analysis. *BMJ Open* 2019;9(1):e025036.
- [144] Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. *Adv Ther* 2015;32 (1):69–85.
- [145] Fawsitt CG et al. A cost-effectiveness and budget impact analysis of C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care settings in Ireland: a decision-analytic model. *Fam Pract* 2021.
- [146] Woodhead M et al. Guidelines for the management of adult lower respiratory tract infections–full version. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2011;17 Suppl 6(Suppl 6):E1–E59.
- [147] Eccles S et al. Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance. *BMJ* 2014;349.
- [148] Lingerveld D et al. Point-of-care testing in primary care: A systematic review on implementation aspects addressed in test evaluations. *Int J Clin Pract* 2019;73(10):e13392.
- [149] Schilling I et al. Patient and public involvement in clinical research: An introduction. *Z Evid Fortbild Qual Gesundhwes* 2020;155:56–63.
- [150] Gütlin CBM, Erler A, Gensichen J, Hoffman B, Mergenthal K, Müller V, et al. Recruitment of Family Practitioners for Research. *Z Allg Med* 2012;88 (4):173–81.
- [151] Timmer A. Publication bias in trials other than RCTs. *Z Evid Fortbild Qual Gesundhwes* 2011;105(3):194–200.
- [152] Mitra-Majumdar M, Kesselheim AS. Reporting bias in clinical trials: Progress toward transparency and next steps. *PLoS Med* 2022;19(1):e1003894.
- [153] Easterbrook PJ et al. Publication bias in clinical research. *Lancet* 1991;337 (8746):867–72.